The Cancer Genome Atlas and high grade serous ovarian cancer

Gestational trophoblastic disease tumours in high risk patients

Defining and advancing individualised medicine

6th International Workshop on Myeloma Pharmacogenomics and Novel Therapeutics

Analysing the efficacy of treatment through Response Evaluation Criteria in Solid Tumors (RECIST)

Development and expansion of the IFOM-IEO campus

Histology and non-histology driven therapy for soft tissue sarcomas and the Rare Cancers Europe initiative

MET inhibitors for non-small cell lung cancer

Pathology and development of ovarian cancer

Putting the theory of personalised medicine into practice

Trametinib and dabrafenib combination therapy against metastatic melanoma

Personalised cancer medicine and research: Today’s best practice